Adis Journals
Vericiguat summary slide.pptx (501.38 kB)

Vericiguat: First Approval

Download (501.38 kB)
online resource
posted on 2021-03-28, 20:03 authored by Anthony Markham, Sean Duggan


Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd/Springer Nature and Sean Duggan is a salaried employee of Adis International Ltd/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here


Vericiguat (VERQUVOTM; Merck & Co, Bayer AG) is a soluble guanylate cyclase (sGC) stimulator being developed for the treatment of chronic heart failure. Vericiguat stimulates sGC and cGMP production independent of nitric oxide (NO) and enhances the effects of NO by stabilizing the NO-sGC binding. Based on the results of the phase III VICTORIA trial vericiguat was recently approved in the USA for risk reduction in patients with heart failure and ejection fraction <45%. This article summarizes the milestones in the development of vericiguat leading to this first approval.

© Springer Nature Switzerland AG 2021


Usage metrics